Abstract
Although first identified just >4 decades ago, methicillin-resistant Staphylococcus aureus (MRSA) has undergone rapid evolutionary changes and epidemiologic expansion to become a major cause of nosocomial and community-acquired infections worldwide. Increasing resistance to vancomycin among MRSA strains in conjunction with availability of new antibiotics, including daptomycin and linezolid, have increased treatment choices but made clinical treatment decisions more challenging. This article describes the clinical features and management issues of 2 challenging-to-treat manifestations of MRSA infection, bacteremia and/or endocarditis and osteomyelitis. It also presents a brief review of community-associated MRSA infections and preventive strategies directed against MRSA.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Bacteremia / diagnosis
-
Bacteremia / drug therapy
-
Bacteremia / microbiology
-
Bacteremia / pathology*
-
Community-Acquired Infections / diagnosis
-
Community-Acquired Infections / drug therapy
-
Community-Acquired Infections / microbiology
-
Community-Acquired Infections / pathology
-
Cross Infection / diagnosis
-
Cross Infection / drug therapy
-
Cross Infection / microbiology
-
Cross Infection / pathology
-
Endocarditis, Bacterial / diagnosis
-
Endocarditis, Bacterial / drug therapy
-
Endocarditis, Bacterial / microbiology
-
Endocarditis, Bacterial / pathology*
-
Humans
-
Methicillin-Resistant Staphylococcus aureus / isolation & purification*
-
Methicillin-Resistant Staphylococcus aureus / pathogenicity*
-
Osteomyelitis / diagnosis
-
Osteomyelitis / drug therapy
-
Osteomyelitis / microbiology
-
Osteomyelitis / pathology*
-
Staphylococcal Infections / diagnosis
-
Staphylococcal Infections / drug therapy
-
Staphylococcal Infections / microbiology
-
Staphylococcal Infections / pathology*